Jevtana (Cabazitaxel)

Jevtana (cabazitaxel) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

Recommended Dosage:
The recommended dose of Jevtana is based on calculation of the Body Surface Area (BSA), and is 20 mg/m2 administered as a one-hour intravenous (IV) infusion every 3 weeks along with oral prednisone 10 mg administered daily throughout the treatment.

A dose of Jevtana 25 mg/m2 can be used in select patients at the discretion of the treating healthcare provider (HCP).

Premedicate at least 30 minutes before each dose with the following intravenous (IV) medicines to reduce the risk and/or severity of hypersensitivity.

• antihistamine (dexchlorpheniramine 5 mg, odiphenhydramine 25 mg, or equivalent antihistamine),
• corticosteroid (dexamethasone 8 mg or equivalent steroid),
• H2 antagonist.

Antiemetic prophylaxis is recommended and can be given orally or intravenously as needed. Jevtana injection single-dose vial requires two dilutions before administration.

• Treatment with Cabazitaxel 60 mg/1.5 mL may cause serious bone marrow suppression. This may lead to neutropenia, anemia, or thrombocytopenia. Regular blood count monitoring is required. Patients with pre-existing low white blood cell (WBC) counts need to be treated cautiously to avoid life-threatening infections and bleeding risks during or after chemotherapy treatment.
• Elderly patients who received this treatment may experience increased side effects such as diarrhea, fatigue, and infection. Dose adjustments and close monitoring are required. Consider the patient’s overall health, co-existing conditions, and organ function before starting therapy to reduce complications in this population.
• Life-threatening allergic reactions such as itching, rash, breathing difficulty, or anaphylaxis can occur with this medicine. Premedicate with antihistamines and corticosteroids to scale down risk. Stop immediately in case hypersensitivity occurs. Avoid re-administering to those who have experienced serious allergic responses previously.
• Treatment with this medicine can cause vomiting, nausea, diarrhea, and abdominal pain. Serious diarrhea may cause dehydration or electrolyte imbalance. Assess fluid levels and manage symptoms quickly. Supportive care with antiemetics or antidiarrheals is required during and after chemotherapy to maintain patient safety.
• Cases of kidney failure, sometimes fatal, may occur with the use of Cabazitaxel, particularly in those experiencing serious infections or dehydration. Ensure appropriate hydration and closely monitor kidney function before and throughout treatment. Caution is required in patients with pre-existing kidney disease or risk factors.
• Cabazitaxel may cause urinary problems such as cystitis, burning sensation during urination, or increased frequency. Ensure proper hydration to scale down bladder irritation. If symptoms persist, assess for infections or inflammation and manage accordingly with antibiotics or supportive care when required.
• Pulmonary symptoms such as shortness of breath, cough, or interstitial lung disease may occur during this therapy. Monitor respiratory status, mainly in patients with prior lung conditions. Stop treatment and investigate symptoms in case respiratory complications develop during chemotherapy.
• Patients with moderate to serious liver impairment may have increased exposure to Cabazitaxel, increasing the risk of toxicity. Dose modifications or therapy avoidance may be required. Always assess liver function before each dose and monitor carefully throughout the treatment.
• Cabazitaxel 60 mg/1.5 mL can harm the unborn baby and is not recommended during pregnancy. Women of reproductive age should use appropriate contraception during treatment and for numerous months afterward. Inform patients of the risks and advise pregnancy testing before starting therapy in women of childbearing age.
• It is not known whether Cabazitaxel passes into human breast milk. Because of the potential risk of serious side effects in nursing infants, breastfeeding needs to be avoided during therapy. Women should stop nursing during treatment and for a safe period after the last dose, as directed.

What documents are required to import JEVTANA to India?

JEVTANA (cabazitaxel) injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is JEVTANA available in India?

JEVTANA (cabazitaxel injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Jevtana in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

JEVTANA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of JEVTANA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Jevtana 60 mg/1.5 mL injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source Jevtana (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Jevtana®?

Cabazitaxel is the Generic Name for the trade name drug Jevtana®.

What is the Manufacturer's Name of Jevtana®?

Jevtana® is manufactured by Sanofi-Aventis U.S. LLC.

What is the dosage and form of Jevtana® supplied?

Jevtana is supplied in an injection: 60 mg/1.5 mL for intravenous (IV) use.

What are the most common side effects of Jevtana® 60 mg/1.5 mL injection?

The most common side effects of Jevtana® are neutropenia, fatigue, back pain, anemia, vomiting, diarrhea, nausea, asthenia, decreased appetite, hematuria, constipation, and abdominal pain.

How much does Jevtana® 60 mg/1.5 mL injection cost in India?

Prices of Jevtana injection may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Jevtana 60 mg/1.5 mL cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Jevtana® 60 mg/1.5 mL injections be available in SAARC countries?

Apart from Gulf countries, Jevtana® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Jevtana® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Jevtana® 60 mg/1.5 mL injection online in India?

Yes, one can buy Jevtana 60 mg/1.5 mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Jevtana® injection through legal channels.

What are the storage conditions of Jevtana® 60 mg/1.5 mL injections?

Store this therapeutic drug at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Do not refrigerate.